Roivant

This page shows the latest Roivant news and features for those working in and with pharma, biotech and healthcare.

Pfizer and Gero collaborate on fibrotic disease research

In December 2022, Pfizer launched a new company with Roivant Sciences to develop RVT-3101 for inflammatory and fibrotic diseases.

Pfizer and Roivant form new company to develop inflammatory disease drug

Pfizer and Roivant Sciences have launched a new company focused on developing RVT-3101, a fully human monoclonal antibody targeting TL1A, for inflammatory and fibrotic diseases. ... Mayukh Sukhatme, president and chief investment officer of Roivant, said:
Myovant preps US filing for relugolix in prostate cancer

companies in the Roivant Sciences group headed by entrepreneur Vivek Ramaswamy – in September.
Sumitomo Dainippon goes big on biotech with $3bn Roivant deal

The five companies Sumitomo is set to take over from Roivant include Myovant, Urovant, Enzyvant, Altavant and another undisclosed spinout company. ... in this alliance,” said Vivek Ramaswamy, founder and chief executive officer of Roivant.
Myovant has second phase 3 trial to back its uterine fibroids drug

The company, part of the Swiss Roivant group headed by Vivek Ramaswamy, says the LIBERTY 2 trial showed a 71.2% response rate for once-daily relugolix in women with uterine
Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Roivant Sciences subsidiary Metavant licensed US and European rights to the drug last year for $35m upfront, a $15m equity investment and up to $500m in milestone payments.

More from news
Approximately 8 fully matching, plus 12 partially matching documents found.

Pharma deals in May 2015

110. Arena Pharmaceuticals/ Roivant Sciences. Licence agreement. For Nelotanserin a 5-HT2A receptor P2 in behavioural and neuropsychiatric disturbances.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Axovant poaches Allergan’s and Teva’s chief medical and science officers

I am also eager to leverage the Roivant platform to accelerate the development of Axovant’s pipeline.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

No results were found

Add my company

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Healing the Healers: Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs: It’s not a question of ‘if,’ it’s a question of ‘when.’...
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment: Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

Email:
Password: